Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.

Abstract excerpt

BACKGROUND: Available targeted agents (TAs) for the upfront therapy of chronic lymphocytic leukemia (ie, ibrutinib, acalabrutinib, venetoclax) have rarely been compared in head-to-head clinical trials. In search of data for evidence-based treatment decisions, a systematic literature review and network meta-analysis was performed. MATERIALS AND METHODS: The screening process adhered to the Preferred Reporting...

Topics

Join the communities discussing this publication.

• Agammaglobulinaemia Tyrosine Kinase
• Antibodies, Monoclonal, Humanized
• Benzamides
• Bridged Bicyclo Compounds, Heterocyclic
• Piperidines